Clinical Trial: GLU-xx Formulations in Individuals With Impaired Glucose Tolerance

Study Status: Terminated
Recruit Status: Terminated
Study Type: Interventional

Official Title: An Open-label, Dose-finding Pilot Study of Various Formulations of Glucose-lowering Products in Otherwise Healthy Individuals With Impaired Glucose Tolerance

Brief Summary: The purpose of this study is to determine a safe,tolerable and efficacious dose of GLU-xx.

Detailed Summary:
Sponsor: Afexa Life Sciences Inc

Current Primary Outcome: Glucose and insulin response to the Oral Glucose Tolerance Test after administration of GLU-xx formulations [ Time Frame: 14 days ]

Original Primary Outcome: To compare the efficacy of the administration of GLU-xx formulations to reduce the glucose and insulin response to the Oral Glucose Tolerance Test [ Time Frame: 14 days ]

Current Secondary Outcome: Safety and tolerability of GLU-xx formulations [ Time Frame: 14 Days ]

Original Secondary Outcome: To determine a safe and tolerable dose of GLU-xx by measuring glucose and insulin response to the Oral Glucose Tolerance Test [ Time Frame: 14 Days ]

Information By: Afexa Life Sciences Inc

Dates:
Date Received: November 7, 2011
Date Started: February 2011
Date Completion:
Last Updated: January 26, 2012
Last Verified: January 2012